A detailed history of Van Eck Associates Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 6,342,831 shares of GILD stock, worth $572 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
6,342,831
Previous 6,319,984 0.36%
Holding current value
$572 Million
Previous $434 Million 27.6%
% of portfolio
0.69%
Previous 0.62%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$66.59 - $83.99 $1.52 Million - $1.92 Million
22,847 Added 0.36%
6,342,831 $553 Million
Q2 2024

Jul 31, 2024

BUY
$63.15 - $72.88 $47.2 Million - $54.5 Million
747,831 Added 13.42%
6,319,984 $434 Million
Q1 2024

Apr 30, 2024

BUY
$71.58 - $87.29 $41.5 Million - $50.6 Million
579,738 Added 11.61%
5,572,153 $408 Million
Q4 2023

Feb 05, 2024

BUY
$73.27 - $83.09 $33.5 Million - $38 Million
457,576 Added 10.09%
4,992,415 $404 Million
Q3 2023

Nov 08, 2023

BUY
$73.94 - $80.67 $51.9 Million - $56.7 Million
702,342 Added 18.33%
4,534,839 $340 Million
Q2 2023

Aug 03, 2023

BUY
$76.01 - $86.7 $139 Million - $159 Million
1,832,292 Added 91.61%
3,832,497 $295 Million
Q1 2023

May 03, 2023

BUY
$77.31 - $88.08 $1.41 Million - $1.61 Million
18,287 Added 0.92%
2,000,205 $166 Million
Q4 2022

Feb 08, 2023

SELL
$62.32 - $89.47 $105 Million - $150 Million
-1,681,089 Reduced 45.89%
1,981,918 $170 Million
Q3 2022

Oct 27, 2022

SELL
$59.54 - $68.01 $12.3 Million - $14.1 Million
-206,643 Reduced 5.34%
3,663,007 $226 Million
Q2 2022

Aug 03, 2022

BUY
$57.72 - $65.01 $18 Million - $20.3 Million
311,736 Added 8.76%
3,869,650 $239 Million
Q1 2022

May 10, 2022

BUY
$57.92 - $72.58 $13.7 Million - $17.2 Million
236,611 Added 7.12%
3,557,914 $212 Million
Q4 2021

Jan 26, 2022

BUY
$64.88 - $73.64 $9.71 Million - $11 Million
149,594 Added 4.72%
3,321,303 $241 Million
Q3 2021

Nov 03, 2021

BUY
$67.69 - $73.03 $14.1 Million - $15.2 Million
208,266 Added 7.03%
3,171,709 $222 Million
Q2 2021

Aug 10, 2021

BUY
$63.47 - $69.35 $25.6 Million - $28 Million
403,756 Added 15.77%
2,963,443 $204 Million
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $20.6 Million - $23.5 Million
342,846 Added 15.47%
2,559,687 $165 Million
Q4 2020

Feb 09, 2021

BUY
$56.65 - $64.55 $18.8 Million - $21.4 Million
332,288 Added 17.63%
2,216,841 $129 Million
Q3 2020

Nov 12, 2020

BUY
$62.1 - $78.08 $7.8 Million - $9.81 Million
125,630 Added 7.14%
1,884,553 $119 Million
Q2 2020

Aug 10, 2020

BUY
$72.34 - $84.0 $13.2 Million - $15.3 Million
182,106 Added 11.55%
1,758,923 $135 Million
Q1 2020

May 12, 2020

SELL
$62.63 - $80.22 $8.69 Million - $11.1 Million
-138,704 Reduced 8.09%
1,576,817 $118 Million
Q4 2019

Feb 13, 2020

BUY
$61.62 - $67.78 $18.8 Million - $20.7 Million
304,836 Added 21.61%
1,715,521 $111 Million
Q3 2019

Nov 08, 2019

BUY
$62.51 - $69.0 $616,036 - $679,995
9,855 Added 0.7%
1,410,685 $89.4 Million
Q2 2019

Aug 07, 2019

BUY
$61.87 - $69.38 $6.42 Million - $7.2 Million
103,768 Added 8.0%
1,400,830 $94.6 Million
Q1 2019

May 13, 2019

BUY
$62.53 - $70.05 $13.7 Million - $15.3 Million
218,854 Added 20.3%
1,297,062 $84.3 Million
Q4 2018

Feb 12, 2019

BUY
$60.54 - $79.0 $3.08 Million - $4.02 Million
50,893 Added 4.95%
1,078,208 $67.4 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $15.5 Million - $17.2 Million
217,516 Added 26.86%
1,027,315 $79.3 Million
Q2 2018

Aug 13, 2018

SELL
$64.88 - $75.68 $1.89 Million - $2.21 Million
-29,167 Reduced 3.48%
809,799 $57.4 Million
Q1 2018

May 11, 2018

SELL
$72.84 - $88.8 $17.6 Million - $21.4 Million
-241,163 Reduced 22.33%
838,966 $63.3 Million
Q4 2017

Feb 12, 2018

BUY
$71.15 - $83.52 $1.02 Million - $1.2 Million
14,399 Added 1.35%
1,080,129 $77.4 Million
Q3 2017

Nov 09, 2017

SELL
$72.11 - $85.47 $25.8 Million - $30.6 Million
-358,011 Reduced 25.15%
1,065,730 $86.3 Million
Q2 2017

Aug 11, 2017

BUY
N/A
1,423,741
1,423,741 $101 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.